In addition, patients with or without BRAF-mutated melanoma, as well as those with acral and mucosal melanoma, a high tumour burden, or M1a/b baseline metastases, all benefit from nivolumab plus relatlimab versus nivolumab alone [5]. The gene discussed is BRAF; the disease is neoplasm.